TABLE 2.
Type of nodal dissection, number of metastatic lymph nodes (NMLN), total lymph nodes examined (TNLE), 5-year overall survival (OS), and 5-year recurrence-free survival (RFS) according to different staging systems
| n (%) | N2 dissection | Median NMLN (IQR) | Median TNLE (IQR) | 5-Year OS (%) | 5-Year RFS (%) | |
|---|---|---|---|---|---|---|
| AJCC 7th edition | ||||||
| N0 | 116 (54.2) | 29 (25.7)* | 0* | 3.5 (1.5–7)* | 47.3* | 64.9* |
| N1 | 87 (40.7) | 9 (10.3) | 1 (1–2) | 5 (3–9) | 26.4 | 28.8 |
| N2 | 11 (5.1) | 11 (100) | 3 (2–7) | 9 (6–12) | 35.6 | 37.5 |
| LNR | ||||||
| 0 | 116 (54.2) | 29 (25.7) | 0* | 3.5 (1.5–7)* | 47.3* | 64.9* |
| >0 to <0.5 | 60 (28.0) | 15 (25.4) | 1 (1–2) | 7 (4–12) | 36.2 | 38.3 |
| ≥0.5 | 38 (17.8) | 5 (13.2) | 2 (1–3) | 2 (2–5) | 11.1 | 12.5 |
| LODDS | ||||||
| ≤−3 | 22 (10.3) | 12 (54.6)* | 0 | 12 (11–18)* | 70.9* | 80.8* |
| −3 to 0 | 154 (71.9) | 32 (21.2) | 0 (0–1) | 4 (2–7) | 40.4 | 50.6 |
| ≥ 0 | 38 (17.8) | 5 (13.2) | 2 (1–3) | 2 (2–5) | 11.9 | 12.5 |
| NMLN | ||||||
| 0 | 116 (54.2) | 29 (25.7) | 0* | 3.5 (1.5–7)* | 47.3 | 64.9* |
| 1 to 3 | 85 (39.7) | 16 (18.8) | 1 (1–2) | 4 (2–8) | 29.5 | 32.6 |
| ≥4 | 13 (6.1) | 4 (30.8) | 5 (5–7) | 11 (8–22) | 0 | 0 |
IQR interquartile range, AJCC American Joint Committee on Cancer, LNR lymph node ratio, LODDS log odds of metastatic lymph node
*
Significant P value between values in each column (P <0.05)